Stock JAGX JAGUAR HEALTH, INC.
Add to a list
To use this feature you must be a member
Log inSign up

Financials Jaguar Health, Inc.

Equities

JAGX

US47010C7065

Biotechnology & Medical Research

Market Closed - Nasdaq
Other stock markets
 21:00:00 09/05/2024 BST 		5-day change 1st Jan Change
0.3095 USD +15.74% Intraday chart for Jaguar Health, Inc. +5.56% +104.43%
05-06 Jaguar Health Applies for Investigational New Animal Drug Status for Potential Dog Diarrhea Treatment MT
05-06 Jaguar Health, Inc. Establishes New Investigational New Animal Drug File with the Center for Veterinary Medicine of the U.S. Food and Drug Administration CI

Valuation

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Capitalization 1 7,275 4,089 213.4 26.27 7.684 85.49 -
Enterprise Value (EV) 1 7,279 4,089 213.4 26.27 7.684 85.49 85.49
P/E ratio -0.09 x -0.82 x -0.88 x -0.18 x -0.08 x -3.44 x -4.42 x
Yield - - - - - - -
Capitalization / Revenue 1,260 x 436 x 49.2 x 2.2 x - 5.66 x 3.77 x
EV / Revenue 1,260 x 436 x 49.2 x 2.2 x - 5.66 x 3.77 x
EV / EBITDA -322,454,775 x - - - - - -
EV / FCF - - - - - - -
FCF Yield - - - - - - -
Price to Book - - - - - - -
Nbr of stocks (in thousands) 40,368 22,297 2,735 4,030 50,756 276,216 -
Reference price 2 180.2 183.4 78.00 6.518 0.1514 0.3095 0.3095
Announcement Date 03/04/20 31/03/21 11/03/22 24/03/23 01/04/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Annual data)

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net sales 1 5.775 9.385 4.335 11.96 - 15.11 22.66
EBITDA -22.56 - - - - - -
EBIT 1 -24.3 -26.65 -40.71 -34.42 - -23.88 -18.99
Operating Margin -420.75% -283.93% -939.05% -287.85% - -158.04% -83.8%
Earnings before Tax (EBT) 1 -38.53 -33.81 -52.6 -48.4 - -26.28 -21.39
Net income 1 -44.73 -38.65 -52.6 -47.45 -41.3 -26.28 -21.39
Net margin -774.45% -411.81% -1,213.26% -396.91% - -173.92% -94.4%
EPS 2 -2,027 -225.0 -88.50 -36.18 -1.790 -0.0900 -0.0700
Free Cash Flow - - - - - - -
FCF margin - - - - - - -
FCF Conversion (EBITDA) - - - - - - -
FCF Conversion (Net income) - - - - - - -
Dividend per Share - - - - - - -
Announcement Date 03/04/20 31/03/21 11/03/22 24/03/23 01/04/24 - -
1USD in Million2USD
Estimates

Income Statement Evolution (Quarterly data)

Fiscal Period: December 2021 Q3 2021 Q4 2022 Q1 2022 Q2 2022 Q3 2022 Q4 2023 Q1 2023 Q2 2023 Q3 2024 Q1 2024 Q2 2024 Q3 2024 Q4 2025 Q1
Net sales 1 0.63 2.08 2.625 2.921 3.15 3.26 - 2.676 2.813 2.96 4.01 4.22 3.92 4.44
EBITDA - - - - - - - - - - - - - -
EBIT 1 -9.529 -10.82 -11.75 -6.479 -9.896 -6.286 - -8.102 -8.787 -7.16 -6.11 -6.32 -4.28 -6.3
Operating Margin -1,512.54% -520.29% -447.77% -221.81% -314.16% -192.82% - -302.77% -312.37% -241.89% -152.37% -149.76% -109.18% -141.89%
Earnings before Tax (EBT) 1 -12.19 -14.32 -18.16 -9.39 -12.61 -8.232 - -12.29 -7.904 -7.76 -6.71 -6.92 -4.88 -6.9
Net income 1 -12.19 -14.31 -17.99 -9.367 -12.52 -7.581 -12.2 -12.15 -7.778 -7.76 -6.71 -6.92 -4.88 -6.9
Net margin -1,935.24% -688.12% -685.18% -320.68% -397.46% -232.55% - -454.04% -276.5% -262.16% -167.33% -163.98% -124.49% -155.41%
EPS 2 -20.25 -23.25 -30.00 -9.000 -9.000 - -2.390 -0.6900 -0.3800 -0.0300 -0.0200 -0.0200 -0.0200 -0.0200
Dividend per Share - - - - - - - - - - - - - -
Announcement Date 17/11/21 11/03/22 10/05/22 22/08/22 14/11/22 24/03/23 15/05/23 14/08/23 14/11/23 - - - - -
1USD in Million2USD
Estimates

Balance Sheet Analysis

Fiscal Period: December 2019 2020 2021 2022 2023 2024 2025
Net Debt 3.73 - - - - - -
Net Cash position - - - - - - -
Leverage (Debt/EBITDA) -0.1655 x - - - - - -
Free Cash Flow - - - - - - -
ROE (net income / shareholders' equity) - - - - - - -
ROA (Net income/ Total Assets) - - - - - - -
Assets 1 - - - - - - -
Book Value Per Share - - - - - - -
Cash Flow per Share - - - - - - -
Capex 1 - - 0.01 0.08 - 0.01 0.01
Capex / Sales - - 0.14% 0.64% - 0.07% 0.04%
Announcement Date 03/04/20 31/03/21 11/03/22 24/03/23 01/04/24 - -
1USD in Million
Estimates

EPS & Dividend

Year-on-year evolution of the PER

Change in Enterprise Value/EBITDA

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
1
Last Close Price
0.3095 USD
Average target price
0.6 USD
Spread / Average Target
+93.86%
Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

1st Jan change Capi.
JAGUAR HEALTH, INC. Stock Jaguar Health, Inc.
+104.43% 85.49M
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+2.97% 108B
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+10.21% 104B
ARGENX SE Stock argenx SE
+2.21% 22.33B
BIONTECH SE Stock BioNTech SE
-12.77% 22.19B
GENMAB A/S Stock Genmab A/S
-7.05% 18.69B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-37.64% 17.74B
BEIGENE, LTD. Stock BeiGene, Ltd.
-6.50% 17.64B
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+6.00% 14.05B
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+37.20% 12.51B
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. JAGX Stock
  4. Financials Jaguar Health, Inc.